

Vascular Anomalies:

1. Vascular tumors:

a. Benign:

- I. Infantile hemangioma
- II. Congenital hemangioma:
 1. Rapidly Involuting Congenital hemangioma (RICH)
 2. Non-Involuting Congenital hemangioma (NICH)
 3. Partially Involuting Congenital hemangioma (PICH)

III. Tufted angioma

b. Borderline / locally aggressive:

- I. Kaposiform
- II. Hemangioendothelioma
- III. Kaposi Sarcoma

c. Malignant

- I. Angiosarcoma

d. Associated with other lesions:

Posterior fossa malformations
Hemangioma
Arterial anomalies
Cardiovascular anomalies
Eye anomalies

Sternal cleft/ supraumbilical raphe

2. Vascular anomalies

a. Simple:

I. Slow flow:



1. Capillary malformations (CM)
2. Venous malformations (VM)
3. Lymphatic malformations (LM)


II. High flow:






1. Arteriovenous malformations (AVM)
2. Arteriovenous fistula (AVF)


b. Combined:

- I. CVM
- II. CLM
- III. LVM
- IV. CAVM

Benign Vascular Tumors	Presentation	Features	Management / Treatment	Picture
Infantile Hemangioma (Strawberry naevi)	<p>head /neck</p> <p>Stage 1 (5-8 m): Rapid disfiguring growth, soft and warm, with a prominent Doppler signal.</p> <p>Stage 2 (7-9 y): prolonged, darkening with grey hue, slow loss of color, fine capillary telangiectasia</p> <p>Stage 3 (7-9 y): visible soft lump regression, cellular parenchyma replaced with fibro-fatty residue</p>	<p>Localized / diffused</p> <p>Expression of GLUT-1 protein</p> <p>histological resemblance to placental tissue</p> <p>PHACE association</p>	<p>Expectant, Rarely biopsy CBC MRI/ US</p> <p>active intervention:</p> <ul style="list-style-type: none"> - large size/ disfigurement - multiple lesions causing high-output cardiac failure - obstruction of vital structures (vision, airway) - persistent ulceration. <p>1st line: Propranolol: Cause vasoconstriction 1-2mg/kg/d</p> <p>2nd line: steroids: Intralesional 2mg/kg (4-6 w) Systemic therapy: Rebound growth</p> <p>Embolization: in high output cardiac failure / bleeding lesions</p> <p>surgical excision, Tracheostomy</p> <p>Pulse-dye laser: in surface residual telangiectasia (>10 y) coagulate surface of ulcerated lesions (dressing is 1ry care)</p>	
RICH	<p>Large mass on leg</p> <p>Faster involution, full regression by 1 year of age</p>	<p>negative for GLUT-1</p> <p>firmer than infantile haemangiomas, with or without telangiectatic changes</p> <p>Leave plaque-like residuum, may regress leaving atrophic patch of skin</p>		

<p>NICH</p>	<p>mimic infantile haemangiomas and of similar texture</p>	<p>round /oval masses, with flat shape or moderately bossed and accompanying telangiectasia, and may have a halo. do not exhibit further growth and do not regress</p>	<p>Expectant management surgical excision</p>	
<p>PICH</p>	<p>variant which looks like a NICH but slowly regresses by age 10</p>	<p>-</p>		
<p>Pyogenic granuloma (PG) Lobular Capillary Hemangioma</p>	<p>starts as small red papule that grows rapidly over weeks to months and then stabilizes</p>	<p>Rapid growth, friable surface: bleeds profusely after minor trauma and may become ulcerated. Bleeding difficult to control recurrent</p>		
<p>Tufted Angioma</p>	<p>Round or oval masses, flat shape or moderately bossed, telangiectasia, no growth or regression</p>	<p>-</p>	<p>Expectant management Observation, may require surgical excision</p>	
<p>Kaposiform (locally aggressive)</p>	<p>Kasabach-Merritt phenomenon KMP</p>		<p>MTOR +ve : Sirolimus</p>	


Vascular malformations	presentation	features	management	picture
CM	Port wine stain (newborns)	colour deformity may cause psychological concern and impair normal social interaction. – In teenager and adults tissue hypertrophy may cause further concern	supportive with involvement of a clinical psychologist, with camouflage and the use of pulse dye laser therapy. – Which can lighten the colour for a number of years. Surgery may be useful for reducing hypertrophied areas: the lower lip	
Nevus simplex (macular stain, salmon patch, stork bite, angel kiss)	single or multiple blanchable, pink-red patches in newborn infants (infants) most commonly on eyelid, glabella, and midline of nape of neck. Less common sites: scalp, nose, lip, and back	generally fades within one to two years, although lesions on the back of the neck may persist unchanged with little consequence	 	
VM	Disfigurement Pain Coagulopathy: D-dimer/ fibrinogen	low-flow lesions are blue, compressible soft tissue masses that empty on elevation. They can affect most tissues 5% genetic abnormalities – Krit-1, TIE-2 and Glomulin genes – Blue rubber bleb syndrome	Compression garments NSAIDS Sclerotherapy Surgery	
Combined Lesions	significant morbidity with painful, heavy areas involving a limb,	isolated or associated with overgrowth disorders such as Klippel- Trenaunay and Proteus syndrome	require life-long care	

	episodes of infection, wound breakdown			
LM	-	Microcystic / macrocystic	Sclerotherapy – OK-432 Surgery – Seroma – Infection	 <p>Figure 8 Lymphatic malformations. (a) macrocystic of the neck that responded well to sclerotherapy. (b) microcystic lesions of the lip that did not respond to sclerotherapy and caused infection, leading to excision of the area.</p>
AVM	<p>Schobinger classification:</p> <p>Stage 1 (Quiescence): pink/ blue stain, warmth, AV shunt</p> <p>Stage 2 (Expansion): Stage 1 + enlargement, pulsations, thrills, bruits</p> <p>Stage 3 (Destruction): Stage 2 + dystrophic skin changes, ulceration, bleeding, pain / tissue necrosis</p> <p>Stage 4 (Decomposition): Stage 3 + high output cardiac failure</p>	High-Flow Lesions, Characteristic nidus with arterial feeders, arteriovenous fistulas, enlarged veins	<p>symptomatic stages (III and IV): Interventional radiology, surgical excision, reconstruction, repeated embolization</p> <p>Embolic agents include • ethanol, cyanoacrylate (glue), coils, polyvinyl particles and onyx, a liquid ethylene vinyl alcohol copolymer</p>	

Molecular mechanism:

The mammalian target of rapamycin (MTOR) pathway²² is an intra- cellular signalling pathway which results in cell growth and survival

The mammalian target of rapamycin (MTOR) pathway



Adapted from Dienstmann, 2014.²³

Figure 10 The mammalian target of rapamycin (MTOR) pathway Adapted from Dienstmann, 2014.²²